Alexa

Roche to take over Genentech in $47BN deal

Roche to take over Genentech in $47BN deal

Roche says it has agreed with Genentech to buy remaining shares of the U.S.-based company for $46.8 billion, in a takeover described as the largest in Swiss corporate history.
The deal announced Thursday for $95 a share of outstanding Genentech stock ends a long struggle between the Basel-based pharmaceutical giant and the board of its cancer-drug partner Genentech.
Roche, which already owns 56 percent of Genentech stock, had increased its bid to $93 per share last Friday after its $86.50-per-share offer failed to pick up support from shareholders of the California-based company.
Originally Roche had offered $89 per share but the Genentech board rejected that as too low.


Updated : 2021-03-06 07:55 GMT+08:00